Xilio Therapeutics, Inc. (NASDAQ:XLO – Get Free Report) saw a significant decrease in short interest in October. As of October 15th, there was short interest totalling 104,800 shares, a decrease of 25.2% from the September 30th total of 140,100 shares. Currently, 0.5% of the company’s stock are sold short. Based on an average trading volume of 148,900 shares, the short-interest ratio is presently 0.7 days.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Xilio Therapeutics stock. Renaissance Technologies LLC lifted its stake in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO – Free Report) by 18.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 295,000 shares of the company’s stock after purchasing an additional 45,554 shares during the period. Renaissance Technologies LLC owned 0.80% of Xilio Therapeutics worth $280,000 at the end of the most recent quarter. 54.29% of the stock is owned by hedge funds and other institutional investors.
Xilio Therapeutics Price Performance
Shares of XLO traded up $0.02 during midday trading on Friday, hitting $0.95. The stock had a trading volume of 168,429 shares, compared to its average volume of 528,876. The firm has a market cap of $35.07 million, a price-to-earnings ratio of -0.37 and a beta of -0.10. The company has a 50 day simple moving average of $0.82 and a two-hundred day simple moving average of $0.95. Xilio Therapeutics has a twelve month low of $0.49 and a twelve month high of $2.89.
About Xilio Therapeutics
Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.
Featured Articles
- Five stocks we like better than Xilio Therapeutics
- Using the MarketBeat Dividend Yield Calculator
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What is the Shanghai Stock Exchange Composite Index?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Investing In Automotive Stocks
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.